Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Genomic profiling in Down syndrome pediatric acute lymphoblastic leukemia

ABSTRACT: Patients with Down syndrome (DS) and acute lymphoblastic leukemia (ALL) have distinct clinical and biological features. Whereas most DS-ALL cases lack the sentinel cytogenetic lesions that guide risk assignment in childhood ALL, JAK2 mutations and CRLF2 overexpression are highly enriched. To further characterize the unique biology of DS-ALL, we performed genome-wide profiling of 58 DS-ALL and 35 non-Down syndrome (NDS) ALL cases by DNA copy number, loss of heterozygosity, gene expression, and methylation analyses. We report novel deletions within the 6p22 histone gene cluster as significantly more frequent in DS-ALL, occurring in 12 DS (24%) and only a single NDS case (3%) (Fisher’s exact p = 0.013). Homozygous deletions yielded significantly lower histone expression levels, and were associated with higher methylation levels, distinct spatial localization of methylated promoters, and enrichment of highly methylated genes for specific pathways and transcription factor binding motifs. Gene expression profiling identified CRLF2 overexpression in nearly half DS-ALL cases, and supervised analysis identified an associated 39-gene signature. However, no expression signature was identified for DS-ALL overall, nor for histone status, suggesting that DS-ALL constitutes several, heterogeneous molecular entities. Characterization of pathways associated with histone deletions and high CRLF2 expression may identify opportunities for novel targeted interventions. This SuperSeries is composed of the SubSeries listed below.

OTHER RELATED OMICS DATASETS IN: PRJNA129677PRJNA129649PRJNA129633PRJNA126695

ORGANISM(S): Homo sapiens

PROVIDER: GSE21094 | GEO | 2011/07/12

SECONDARY ACCESSION(S): PRJNA126695

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Expression data from Down syndrome and non-Down syndrome pediatric acute lymphoblastic leukemia cases

2011-07-12 | GSE20910 | GEO

Expression data from Down syndrome and non-Down syndrome pediatric acute lymphoblastic leukemia cases

Project description:Gene expression profiling (GEP) can reveal characteristic signatures associated with distinct biologic subtypes of acute lymphoblastic leukemia (ALL). We performed GEP on Down syndrome (DS) and comparison non-Down syndrome (NDS) ALL cases to identify biologic differences between these groups. Ficoll-enriched, cryopreserved diagnostic bone marrow samples were obtained from patients with newly diagnosed B-precursor acute lymphoblastic leukemia.

2011-07-12 | E-GEOD-20910 | biostudies-arrayexpress

Aberrant astrocyte protein secretion contributes to altered neuronal development in diverse disorders

Project description:Astrocytes negatively impact neuronal development in a range of neurodevelopmental disorders (NDs), however how they do this, and if mechanisms are shared across multiple disorders, is not known. We developed an in vitro system to ask how astrocyte protein secretion and gene expression change in 3 genetic NDs (Fragile X syndrome (FXS), Rett's syndrome (RTT), Down's syndrome (DS)). This identified disorder specific changes, as well as core proteins that are increased in release in all 3 NDs. We provide a resource of astrocyte secreted proteins and gene expression in health and NDs, as well as novel targets for intervention in diverse NDs.

2022-07-05 | GSE139285 | GEO

Mass spectrometry-based proteomic profiling of exosomal proteins in diabetic and non-diabetic ischemic stroke patients: a case-control study

Project description:This case-control study utilized mass spectrometry-based proteomics to compare exosomes from non-diabetic stroke (nDS=14), diabetic stroke (DS=13), and healthy control (HC=12) subjects. Among 1288 identified proteins, 387 were statistically compared. Statistical comparisons using a general linear model (log2 foldchange 0.58 and FDR-p0.05) were performed for nDS vs. HC, DS vs. HC, and DS vs. nDS. DS vs. HC and DS vs. nDS comparisons produced 155 and 159 differentially expressed proteins, respectively.

2024-06-03 | PXD047674 | Pride

Down's syndrome with acute lymphoblastic pediatric leukemia (DS-ALL)

Project description:DS-ALL is a highly heterogeneous disease with predominance of an aberrant exp. of CRLF2 cooperating with mutated JAK2 Acute lymphoblastic pediatric leukemia specimens of Down's syndrome are examined for gene expression profiles and specific genetic aberrations. Gene expression profiling and specific genetic variation analysis identify novel pathways involved in DS-ALL pathogenesis.

2010-01-13 | GSE17459 | GEO

Affymetrix SNP 6.0 data for individuals with Trisomy 21 or Down syndrome

Project description:Individuals with Down syndrome (DS) are at an increased risk for developing congenital heart defects especially atrioventricular septal defects (AVSD). Our goal was to identify the contribution of copy number variants (CNV) to DS-associated AVSD. We used the Affymetrix SNP 6.0 genotyping platform to comprehensively characterize CNVs in 452 ethnically matched individuals with DS, comprising of 210 cases (DS + complete AVSD) and 242 controls with a structurally normal heart (DS + NH). Results from burden and region-wise analyses using PLINK revealed that despite the 2000 fold elevated risk, common CNVs of large effect (OR > 2.0) do not account for the increased risk observed in DS-associated AVSD. In contrast, cases do harbor a significantly elevated burden of large rare variants (> 100kb, < 1% frequency) (p < 0.01) and case deletions intersect genes more often than those observed in controls (p < 0.007). Gene enrichment analysis showed a trend for enrichment among deletions impacting the ciliome pathway in cases compared to controls. Our findings suggest that the etiology of AVSD is highly complex and does not arise from the action of a few common variants of large effect. Instead, our data support a multifactorial model, wherein large rare deletions play a significant role in elevating the risk of AVSD in a trisomic background.

2014-10-24 | GSE60607 | GEO

Transcription profiling of human Downs syndrome with acute lymphoblastic pediatric leukemia (DS-ALL) patients

Project description:DS-ALL is a highly heterogeneous disease with predominance of an aberrant exp. of CRLF2 cooperating with mutated JAK2; Acute lymphoblastic pediatric leukemia specimens of Down's syndrome are examined for gene expression profiles and specific genetic aberrations. Gene expression profiling and specific genetic variation analysis identify novel pathways involved in DS-ALL pathogenesis. Experiment Overall Design: Gene expression profile analysis and specific genetic data are integrated to find characteristics of DS-ALL's

2010-01-15 | E-GEOD-17459 | biostudies-arrayexpress

Affymetrix SNP 6.0 data for individuals with Trisomy 21 or Down syndrome

2014-10-24 | E-GEOD-60607 | biostudies-arrayexpress

Rearrangement of CRLF2 in B-progenitor and Down syndrome associated acute lymphoblastic leukemia

Project description:Chromosomal aneuploidy and translocations are hallmarks of acute lymphoblastic leukemia (ALL), but many patients lack a recurring chromosomal alteration. Here we report a recurring interstitial deletion of the pseudoautosomal region 1 of chromosomes X and Y in B-progenitor ALL that results in the expression of a novel fusion that juxtaposes the first non-coding exon of P2RY8 to the coding region of the CRLF2 (cytokine receptor like factor 2, or thymic stromal lymphopoietin receptor) gene. The P2RY8-CRLF2 fusion was identified in 7% of B-ALL cases, and was very common in ALL associated with Down syndrome (55% of cases) and was associated with the presence of JAK mutations. The P2RY8-CRLF2 fusion results in increased expression of CRLF2, a lymphoid signaling molecule that forms a heterodimeric complex with interleukin receptor 7 alpha. These findings identify a novel recurring chromosomal alteration in B-ALL, and suggest that perturbed CRLF2-mediated signaling is a key event in leukemogenesis in these cases. Profiling of tumor acquired DNA copy number alterations in 2 patients with Down syndrome associated B-progenitor acute lymphoblastic leukemia. Matched tumor and normal DNA was used for each array hybridization in each case.

2009-10-18 | E-GEOD-16724 | biostudies-arrayexpress

Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in BCP-ALL

Project description:Deregulated expression of cytokine receptor gene, CRLF2, is involved in lymphoid transformation in B-cell precursor acute lymphoblastic leukemia We report two novel, cryptic chromosomal abnormalities in precursor B-cell acute lymphoblastic leukemia (BCP-ALL): a translocation, either t(X;14)(p22;q32) or t(Y;14)(p11;q32), in 33 patients and an interstitial deletion, either del(X)(p22.33p22.33) or del(Y)(p11.32p11.32), in 64 patients, involving the pseudoautosomal region (PAR1) of the sex chromosomes. The incidence of these abnormalities was 5% in childhood ALL (0.8% with the translocation, 4.2% with the deletion). Patients with the translocation were older (median age 16 years), whilst the patients with the deletion were younger (median age 4 years). The two abnormalities result in deregulated expression of the cytokine receptor, cytokine receptor-like factor 2, CRLF2 (also known as thymic stromal-derived lymphopoietin receptor, TSLPR). Over-expression of CRLF2 was associated with activation of the JAK-STAT pathway in cell lines and transduced primary B-cell progenitors, sustaining their proliferation and indicating a causal role of CRLF2 over-expression in lymphoid transformation. In Down Syndrome (DS) ALL and two non DS BCP-ALL cell lines, CRLF2 deregulation was associated with mutations of the JAK2 pseudokinase domain suggesting oncogenic cooperation, as well as highlighting a link between non DS ALL and JAK2 mutations. Keyword(s): Global copy number analysis using Agilent oligonucleotide arrays

2009-07-18 | GSE17165 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data